Workflow
AptarGroup(ATR)
icon
Search documents
4 Stocks to Buy on Steady Rebound in Manufacturing Activity
ZACKS· 2025-07-07 13:16
Industry Overview - The U.S. manufacturing sector is showing signs of recovery after a prolonged downturn, with new orders for manufactured goods increasing by 8.2% in May compared to a revised 3.9% decline in April, and a year-over-year increase of 3.2% [3][4] - The rebound in manufacturing activity is supported by easing inflationary pressures and expectations of Federal Reserve rate cuts, which are anticipated to boost demand [1][6][11] Manufacturing Activity - The Institute of Supply Management's manufacturing PMI rose to 49 in June from 48.5 in May, indicating a continued contraction but a rebound from a six-month low [5][6] - Manufacturing activity accounts for 10.2% of the U.S. economy, highlighting its significance [5] Stock Recommendations - Four stocks from the manufacturing sector are recommended for investment: Allegion plc (ALLE), AptarGroup, Inc. (ATR), Broadwind, Inc. (BWEN), and DXP Enterprises, Inc. (DXPE), all of which have strong earnings growth prospects and Zacks Rank of 1 (Strong Buy) or 2 (Buy) [2][11] Allegion plc (ALLE) - Allegion is a global provider of security products and solutions, with an expected earnings growth of 3.9% for the current year and a Zacks Rank 2 [8][9] AptarGroup, Inc. (ATR) - AptarGroup specializes in innovative dispensing and packaging solutions, with an expected earnings growth of 4.1% for the current year and a Zacks Rank 2 [12][13] Broadwind, Inc. (BWEN) - Broadwind is a precision manufacturer focused on clean tech, particularly in the U.S. wind energy sector, with an expected earnings growth of 60% for the current year and a Zacks Rank 2 [14][15] DXP Enterprises, Inc. (DXPE) - DXP Enterprises is a distributor providing innovative solutions to industrial customers, with an expected earnings growth rate of 17.5% for the current year and a Zacks Rank 2 [16][17]
CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR
Prnewswire· 2025-07-02 11:00
Core Viewpoint - CytoSorbents Corporation is actively pursuing regulatory approvals for its DrugSorb™-ATR device, aimed at reducing perioperative bleeding in patients undergoing CABG surgery who are on the antiplatelet drug Brilinta® [1][4] Regulatory Updates - The FDA has scheduled an appeal hearing for CytoSorbents' supervisory review of its De Novo Request, with expectations to resolve deficiencies by the end of August 2025 [2] - Health Canada issued a Notice of Refusal for the Medical Device License application, prompting the company to file a Request for Reconsideration by July 25, 2025 [3] Product Overview - DrugSorb-ATR is designed to address a significant need in cardiac surgery by mitigating bleeding risks associated with Brilinta® [4] - The device has received FDA Breakthrough Device Designation for removing ticagrelor and other direct oral anticoagulants during cardiothoracic procedures [8] Company Background - CytoSorbents specializes in blood purification therapies for critical conditions, utilizing proprietary polymer bead technology to remove toxins from blood [5] - The company's lead product, CytoSorb®, is already approved in the EU and has been used over 270,000 times globally [6]
投资比特币Locate Technologies (ASX:LOC) 股价连番暴涨
Sou Hu Cai Jing· 2025-06-27 13:39
Group 1: Locate Technologies (ASX: LOC) - Locate Technologies' stock price surged by 42.86% to 0.25 AUD, with a market capitalization of 57.58 million AUD and 230 million shares issued [3] - The stock price increased from 0.115 AUD to a peak of 0.28 AUD, representing a 144% rise, with significant trading volume prompting inquiries from the Australian Stock Exchange [3][4] - The company has invested 1.62 million AUD in Bitcoin, continuing to allocate excess cash reserves towards this investment [4] Group 2: Astron Corporation (ASX: ATR) - Astron Corporation's stock price jumped by 47.13% to 0.64 AUD, with a market capitalization of 133 million AUD and 210 million shares issued [10] - The Victorian government approved the Donald rare earth sands project, which is expected to produce significant rare earth elements, enhancing the project's global importance [10] - The project has received all major regulatory approvals necessary for financing arrangements [10] Group 3: Li-S Energy (ASX: LIS) - Li-S Energy's stock price rose by 23.66% to 0.115 AUD, with a market capitalization of 73.62 million AUD and 640 million shares issued [14] - The company signed a collaboration and battery supply agreement with a leading defense technology company to test the performance and safety of its lithium-sulfur batteries in defense applications [14] - Li-S Energy plans to accelerate its entry into key global markets, including defense, with the installation of a 2MWh production and testing facility [14]
CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR
Prnewswire· 2025-06-24 11:00
Core Viewpoint - CytoSorbents Corporation has filed a request for supervisory review with the FDA regarding the De Novo Denial Letter for its DrugSorb-ATR Device, which aims to reduce bleeding severity in CABG surgery patients on Brilinta® [1][2][7] Group 1: Company Overview - CytoSorbents Corporation specializes in blood purification technologies for treating life-threatening conditions in intensive care and cardiac surgery [5] - The company's proprietary technologies utilize biocompatible polymer beads to remove toxic substances from blood, applicable in various medical scenarios including sepsis and organ failure [5][6] - CytoSorbents' lead product, CytoSorb®, is CE Marked in the EU and has been used over 270,000 times globally [6] Group 2: Regulatory Developments - The FDA issued a De Novo Denial Letter on April 25, 2025, citing deficiencies that must be resolved before the DrugSorb-ATR can be authorized for U.S. commercialization [2][7] - The company has engaged with the FDA to clarify these deficiencies and believes that the supervisory review process will effectively address the concerns [2][4] - The appeals process typically results in a final decision approximately 60 days after filing, with the company optimistic about receiving a regulatory decision in 2025 [3][7] Group 3: Market Context - DrugSorb-ATR is designed to mitigate perioperative bleeding in patients undergoing high-risk surgeries while on antithrombotic medications [7] - The application for DrugSorb-ATR is also under advanced review by Health Canada, with the agency committed to issuing a decision despite current delays [4][7]
AptarGroup (ATR) Upgraded to Strong Buy: Here's Why
ZACKS· 2025-06-20 17:00
Core Viewpoint - AptarGroup (ATR) has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which are crucial for stock price movements [1][2][4] Earnings Estimates and Stock Price Impact - Changes in a company's future earnings potential, reflected in earnings estimate revisions, are strongly correlated with near-term stock price movements, influenced by institutional investors [3] - The Zacks rating system effectively captures the power of earnings estimate revisions, making it a valuable tool for investors [5][6] AptarGroup's Earnings Outlook - AptarGroup is expected to earn $5.87 per share for the fiscal year ending December 2025, with no year-over-year change, but the Zacks Consensus Estimate has increased by 5.5% over the past three months [7] - The upgrade to Zacks Rank 1 places AptarGroup in the top 5% of Zacks-covered stocks, suggesting potential for higher stock movement in the near term [9]
ATR and RTX's Pratt & Whitney Canada collaborate on propulsion technology to advance next-generation regional turboprops
Prnewswire· 2025-06-16 12:30
Companies will target continued improvements to aircraft fuel efficiency, durability and operating costsPARIS, June 16, 2025 /PRNewswire/ -- ATR and Pratt & Whitney Canada today announce their intent to collaborate on the development of advanced propulsion technology for regional turboprop aircraft, shaping the future of low-emission regional aviation. This collaboration aims to leverage and extend the industry-leading performance of ATR aircraft equipped with Pratt & Whitney Canada PW127XT engines and expl ...
AptarGroup (ATR) 2025 Conference Transcript
2025-06-04 19:00
AptarGroup (ATR) 2025 Conference June 04, 2025 02:00 PM ET Speaker0 Afternoon. I'm Dan Rizzo with Jefferies Equity Research. Presenting now is Aptar Group, and with us today is CEO, Stefan Tanda, and CFO, Vanessa Cano. There'll be a presentation, but there should be time at the end for questions. So with that, I will turn it over to Stefan. Thanks. Speaker1 Alright, Dan. Thanks for having us. It's my pleasure to introduce you to Aptar Group. It's, I think, our inaugural presence at this, conference. The rea ...
AptarGroup (ATR) FY Conference Transcript
2025-06-03 14:40
Summary of the Conference Call Company Overview - The company discussed is Aptar, which operates primarily in the pharmaceutical, beauty, personal care, home care, food, and beverage sectors [2][3][5] - Approximately 46% of Aptar's business is in the pharmaceutical sector, which is the most profitable and rapidly growing segment [3][11] Key Business Segments Pharmaceutical Business - The pharmaceutical segment includes proprietary dispensing devices such as nasal sprays and injectables, notably GLP-1 [3][11] - The company has increased its core sales growth rate for the pharmaceutical business to 7-11% from a previous range of 6-10% [11] - The pharmaceutical business has a compound annual growth rate (CAGR) of about 8% over the last decade [11] - The segment contributes nearly 70% of the company's EBITDA [17] Beauty and Personal Care - The beauty segment has faced challenges but is expected to improve due to cost improvements and productivity enhancements [12][34] - China is a significant market for beauty products, with the average consumer basket containing twice as many beauty products compared to the West [34][55] - The company has undergone a significant renovation process in its beauty business, including upgrading assets and reducing non-competitive plants [34] Closures Business - The closures segment is known for innovative products like the upside-down ketchup bottle, which has expanded into various condiments and personal care products [36][38] - This segment is primarily US-focused and has been able to drive growth through converting markets to use Aptar's products [41] Financial Performance and Targets - The adjusted EBITDA target for the total company has been increased to 21-23% [11] - The return on invested capital target has been raised to 11-13% [11] - The company has returned nearly $800 million to shareholders through dividends and share buybacks from 2019 to 2024 [13] - The company maintains a strong balance sheet with a leverage ratio of 1.16, allowing for continued investment in growth opportunities [14] Sustainability and Competitive Advantage - Sustainability is a core part of Aptar's business model, providing a competitive advantage [7][15] - The company has received recognition for its sustainability efforts, including being in the top 1% of companies ranked by EcoVadis [15][16] Market Trends and Growth Drivers - There is a trend of repurposing existing drugs for nasal delivery, which is driving growth in the pharmaceutical segment [22][24] - The rise in allergic rhinitis cases, particularly in Asia, is another growth driver for the pharmaceutical business [24][25] - The company benefits from its intellectual property, allowing it to maintain revenue even when products go generic or over-the-counter [25][26] Customer Dynamics and Market Conditions - Customer conversations indicate a cautious approach to strategic actions due to ongoing tariff uncertainties [45][46] - The company has observed a resurgence in consumer confidence in China, which is expected to positively impact the beauty segment [54][55] Conclusion - Aptar is positioned for long-term growth with a focus on innovation, sustainability, and a strong balance sheet, despite facing challenges in certain segments [11][12][14]
Buy 4 Low-Beta Stocks NGS, LRN, ATR & PM Despite Court Tariff Ruling
ZACKS· 2025-05-29 15:05
Market Overview - A recent ruling by the U.S. trade court declared President Trump's global tariffs illegal, contributing to a new wave of market uncertainty [1] - The Federal Reserve's current wait-and-see approach adds to the uncertainty regarding future interest rate directions [1] Investment Strategy - Creating a curated portfolio of low-beta stocks is recommended as a strategy to navigate market volatility [1] - Low-beta stocks are less volatile than the market, providing a safeguard against uncertainty [1] Stock Recommendations - Suggested stocks include Natural Gas Services Group Inc (NGS), Stride Inc. (LRN), AptarGroup Inc. (ATR), and Philip Morris International Inc. (PM) [2] Stock Characteristics - Beta measures the volatility of a stock relative to the market, with a beta of 1 indicating movement in line with the market [3][4] - Stocks with a beta between 0 and 0.6 are screened for lower volatility [5] Screening Criteria - Stocks must have a positive price change over the last four weeks [5] - Average 20-day trading volume should exceed 50,000 to ensure liquidity [6] - Stocks must be priced at $5 or higher [6] - Zacks Rank of 1 indicates strong buy potential, suggesting significant outperformance over the next one to three months [6] Company Insights - **Natural Gas Services (NGS)**: Increased demand for liquefied natural gas (LNG) exports is driving the need for compression equipment, benefiting NGS as more pipelines are built [7] - **AptarGroup (ATR)**: Positioned for growth due to trends in healthcare moving towards home settings and rising demand for drug delivery systems [8] - **Stride Inc. (LRN)**: Focuses on innovative educational solutions, benefiting from the growing demand for school choice and tutoring services [10] - **Philip Morris International (PM)**: Transitioning from traditional cigarettes to smoke-free products, with a focus on shareholder rewards and cost-cutting initiatives [11]
4 Top-Ranked Efficient Stocks to Buy for Solid Gains Amid Volatility
ZACKS· 2025-05-22 14:05
Core Insights - The article emphasizes the importance of efficiency levels in assessing a company's potential for profitability and price performance [1] - It highlights specific efficiency ratios that can be used to evaluate companies, including Receivables Turnover, Asset Utilization, Inventory Turnover, and Operating Margin [2][3][4][5] Efficiency Ratios - **Receivables Turnover**: This ratio measures a company's ability to extend credit and collect debts, with a higher ratio indicating better performance [2] - **Asset Utilization**: This ratio assesses how effectively a company converts its assets into sales, with higher values suggesting greater efficiency [3] - **Inventory Turnover**: This ratio indicates how well a company manages its inventory relative to its cost of goods sold, with higher values reflecting better inventory management [4] - **Operating Margin**: This ratio evaluates a company's ability to control operating expenses, with higher values indicating more efficient expense management [5] Screening Criteria - The article mentions that companies were screened based on the aforementioned efficiency ratios being greater than industry averages, narrowing down the selection to eight stocks [7] - A favorable Zacks Rank of 1 (Strong Buy) was also included in the screening criteria to enhance profitability [6] Selected Companies - **Microvast (MVST)**: A technology company specializing in lithium-ion battery solutions, with an average four-quarter earnings surprise of 88.8% [8] - **Companhia de saneamento Basico Do Estado De Sao Paulo Sabesp (SBS)**: Provides public water and sewage services in Sao Paulo, with an average four-quarter earnings surprise of 30.8% [8] - **CarGurus (CARG)**: An online automotive marketplace with an average four-quarter earnings surprise of nearly 11.8% [9] - **AptarGroup (ATR)**: A global supplier of innovative packaging solutions, with an average four-quarter earnings surprise of nearly 7.3% [9]